Latest Period
Q4 2025
Security Snapshot
Arcutis Biotherapeutics, Inc. - Common (ARQT) Institutional Ownership
CUSIP: 03969K108
13F Institutional Holders and Ownership History from Q1 2020 to Q1 2026
Institutions Reporting
278
Shares (Excl. Options)
128,945,244
Price
$29.04
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common
- Symbol
- ARQT on Nasdaq
- Shares outstanding
- 123,318,907
- Price per share
- $24.12
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 128,945,244
- Total reported value
- $3,743,980,096
- % of total 13F portfolios
- 0.01%
- Share change
- +2,607,316
- Value change
- +$103,364,675
- Number of holders
- 278
- Price from insider filings
- $24.12
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ARQT - Arcutis Biotherapeutics, Inc. - Common is tracked under CUSIP 03969K108.
- 278 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 278 to 98 between Q4 2025 and Q1 2026.
- Reported value moved from $3,743,980,096 to $592,462,798.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 278 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 03969K108?
CUSIP 03969K108 identifies ARQT - Arcutis Biotherapeutics, Inc. - Common in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03969K108:
Significant Owners of Arcutis Biotherapeutics, Inc. - Common (ARQT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Frazier Life Sciences VIII, L.P. | 7.5% | $130,399,321 | 8,943,712 | Patrick J. Heron | 18 Aug 2025 | |||
| Rubric Capital Management LP | 6.8% | $239,875,733 | 8,271,577 | Rubric Capital Management LP | 31 Dec 2025 | |||
| PRUDENTIAL FINANCIAL INC | 4.3% | -23% | $127,901,438 | -$42,866,378 | 5,302,713 | -25% | PRUDENTIAL FINANCIAL INC | 31 Mar 2026 |
| Polar Capital Holdings Plc | 4.2% | -24% | $75,147,145 | -$25,517,045 | 5,006,472 | -25% | Polar Capital Holdings Plc | 30 Jun 2025 |
| JENNISON ASSOCIATES LLC | 4% | -25% | $120,136,172 | -$42,866,932 | 4,980,770 | -26% | Jennison Associates LLC | 31 Mar 2026 |
As of 31 Dec 2025, 278 institutional investors reported holding 128,945,244 shares of Arcutis Biotherapeutics, Inc. - Common (ARQT). This represents 105% of the company’s total 123,318,907 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Arcutis Biotherapeutics, Inc. - Common (ARQT) together control 82% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 9.7% | 11,964,000 | +14% | 8.7% | $347,434,560 |
| Frazier Life Sciences Management, L.P. | 8% | 9,874,511 | 0% | 7.7% | $286,755,799 |
| BlackRock, Inc. | 7.4% | 9,099,579 | +6.1% | 0% | $264,251,774 |
| Rubric Capital Management LP | 6.7% | 8,271,577 | -23% | 2.9% | $240,206,596 |
| VANGUARD GROUP INC | 5.9% | 7,253,936 | +1.5% | 0% | $210,654,301 |
| JENNISON ASSOCIATES LLC | 5.5% | 6,758,006 | -45% | 0.12% | $196,252,495 |
| Polar Capital Holdings Plc | 4.5% | 5,556,169 | +4.9% | 0.74% | $161,351,148 |
| STATE STREET CORP | 4.5% | 5,488,301 | +18% | 0.01% | $159,380,261 |
| GILDER GAGNON HOWE & CO LLC | 3.6% | 4,453,856 | +0.56% | 1.4% | $129,339,978 |
| MORGAN STANLEY | 3.5% | 4,340,238 | +1.5% | 0.01% | $126,040,515 |
| UBS Group AG | 2.6% | 3,243,432 | +10% | 0.02% | $94,189,265 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 2,753,307 | +5.6% | 0% | $79,967,495 |
| D. E. Shaw & Co., Inc. | 2.2% | 2,683,087 | +27% | 0.06% | $77,916,846 |
| Driehaus Capital Management LLC | 2.1% | 2,562,445 | +134% | 0.51% | $74,413,403 |
| Ensign Peak Advisors, Inc | 1.5% | 1,902,390 | -4.5% | 0.1% | $55,245,406 |
| FRANKLIN RESOURCES INC | 1.5% | 1,900,084 | -18% | 0.01% | $55,178,440 |
| JANUS HENDERSON GROUP PLC | 1.5% | 1,830,061 | -24% | 0.02% | $53,154,122 |
| BANK OF AMERICA CORP /DE/ | 1.4% | 1,673,454 | +88% | 0% | $48,597,105 |
| GOLDMAN SACHS GROUP INC | 1.3% | 1,576,413 | -13% | 0.01% | $45,779,034 |
| AMERICAN CENTURY COMPANIES INC | 1.2% | 1,467,176 | -12% | 0.02% | $42,606,849 |
| Nuveen, LLC | 1.1% | 1,382,160 | +0.86% | 0.01% | $40,137,927 |
| Pivotal bioVenture Partners Investment Advisor LLC | 1.1% | 1,366,624 | -36% | 15% | $39,686,761 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.95% | 1,166,348 | +1228% | 0% | $33,872,000 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.82% | 1,014,826 | +1.5% | 0% | $29,470,547 |
| GW&K Investment Management, LLC | 0.82% | 1,008,580 | -14% | 0.25% | $29,289,000 |
Institutional Holders of Arcutis Biotherapeutics, Inc. - Common (ARQT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 25,157,805 | $592,462,798 | -$36,084,613 | $23.56 | 98 |
| 2025 Q4 | 128,945,244 | $3,743,980,096 | +$103,364,675 | $29.04 | 278 |
| 2025 Q3 | 125,804,940 | $2,370,184,094 | -$12,772,142 | $18.85 | 235 |
| 2025 Q2 | 127,080,415 | $1,781,069,063 | +$21,637,125 | $14.02 | 228 |
| 2025 Q1 | 125,020,441 | $1,954,466,256 | -$63,284,061 | $15.64 | 239 |
| 2024 Q4 | 128,710,441 | $1,792,934,402 | +$13,789,213 | $13.93 | 206 |
| 2024 Q3 | 128,641,664 | $1,198,282,493 | +$15,921,001 | $9.30 | 187 |
| 2024 Q2 | 126,503,507 | $1,176,619,915 | +$9,242,287 | $9.30 | 184 |
| 2024 Q1 | 124,986,945 | $1,238,517,575 | +$285,414,998 | $9.91 | 166 |
| 2023 Q4 | 101,272,913 | $327,119,655 | +$79,248,549 | $3.23 | 130 |
| 2023 Q3 | 67,159,664 | $356,705,615 | -$26,597,323 | $5.31 | 131 |
| 2023 Q2 | 71,766,867 | $683,988,878 | -$5,745,956 | $9.53 | 135 |
| 2023 Q1 | 71,600,840 | $787,595,702 | +$44,255,428 | $11.00 | 141 |
| 2022 Q4 | 65,632,382 | $971,340,873 | +$87,400,990 | $14.80 | 138 |
| 2022 Q3 | 59,389,299 | $1,134,920,691 | +$194,978,652 | $19.11 | 138 |
| 2022 Q2 | 49,075,739 | $1,045,833,934 | +$17,642,019 | $21.31 | 112 |
| 2022 Q1 | 48,307,139 | $929,780,885 | -$136,426,148 | $19.26 | 106 |
| 2021 Q4 | 46,348,278 | $961,255,152 | -$1,852,441 | $20.74 | 89 |
| 2021 Q3 | 45,697,453 | $1,091,410,573 | +$4,816,184 | $23.89 | 103 |
| 2021 Q2 | 45,474,760 | $1,240,848,739 | -$38,040,013 | $27.29 | 100 |
| 2021 Q1 | 46,841,365 | $1,354,985,371 | +$170,660,745 | $28.93 | 93 |
| 2020 Q4 | 40,973,719 | $1,152,598,120 | +$138,537,380 | $28.13 | 78 |
| 2020 Q3 | 34,766,158 | $1,018,651,387 | +$28,894,471 | $29.30 | 62 |
| 2020 Q2 | 33,776,828 | $1,021,408,758 | +$33,104,690 | $30.24 | 55 |
| 2020 Q1 | 32,683,658 | $973,975,747 | +$973,295,747 | $29.80 | 49 |